source
- Opinion: FDA commissioner nominee Heidi Overton is ignoring the science on abortion drug“With this latest appointment, mifepristone has a new boss but an old problem,” writes Julie F. Kay, founder and CEO of Reproductive Futures.STAT · 1mo ago↗ source
- STAT+: Pharmalittle: We’re reading about a reticent FDA commish nominee, a Novo deal, and morePresident Trump’s nominee to lead the FDA was grilled by senators on hot button topics like China, vaccines, and abortion accessSTAT · 1mo ago↗ source
- Alnylam alumni lead RNAi biotech City Therapeutics to IPO filingBiotechs are rushing into the IPO queue. City Therapeutics submitted its public pitch late Thursday, the same night ADARx Pharmaceuticals priced its $446 million Nasdaq debut. Kendall Square-based ...